Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Clear Cell Renal Cell Carcinoma
Drug:
sorafenib
(
Multi-tyrosine kinase inhibitor
,
pan-RAF inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
02/03/2021
Excerpt:
Subsequent therapy for Clear cell histology: Useful in certain circumstances…Sorafenib (category 2B).
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login